<?xml version="1.1" encoding="utf-8"?>
<article xsi:noNamespaceSchemaLocation="http://jats.nlm.nih.gov/publishing/1.1/xsd/JATS-journalpublishing1-mathml3.xsd" dtd-version="1.1" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"><front><journal-meta><journal-id journal-id-type="publisher-id">JMDS</journal-id><journal-title-group><journal-title>Journal of Medicines Development Sciences</journal-title></journal-title-group><issn>2382-6363</issn><eissn>2382-6371</eissn><publisher><publisher-name>WHIOCE PUBLISHING PTE. LTD.</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.18063/jmds.v1i1.106</article-id><article-categories><subj-group subj-group-type="heading"><subject>Review Article</subject></subj-group></article-categories><title>European initiatives for better training in  medicines development</title><url>https://artdesignp.com/journal/JMDS/1/1/10.18063/jmds.v1i1.106</url><author>HardmanMike</author><pub-date pub-type="publication-year"><year>2015</year></pub-date><volume>1</volume><issue>1</issue><history><date date-type="pub"><published-time>2015-05-05</published-time></date></history><abstract>&amp;nbsp; In the last decade, the environment for medicines development has undergone unprecedented change, including: a shift from predominantly big Pharma to one of extensive industry&amp;ndash;academia and SME partnerships and collaborations, greater emphasis on understanding the molecular basis of disease for stratified and personalised medicine, and a focus on societal/patients&amp;rsquo; needs and priorities.
&amp;nbsp; A variety of European initiatives have been established to support the training of scientists/professionals involved in medicines development in order to respond to this constantly changing, demanding, and chaotic landscape. Some of these initiatives are directed specifically at medicines development, some address scientific research including training relevant to medicines development, and some support general training needs which can include medicines development.
&amp;nbsp; There are a number of European initiatives supporting better training in medicines development. They differ in their approach, ranging from IMI (specific to medicines development) to Erasmus+ (boosting skills and employability in all areas). The scope, budgets, and requirements differ considerably and they each have to be reviewed in detail to decide which might be the most appropriate for a particular target group. The common theme is to support the aims of the European Research Area (ERA), i.e., a significant improvement in Europe&amp;rsquo;s research performance to promote growth and job creation."</abstract><keywords>IMI, ESFRI BMS Research Infrastructures, Erasmus+, Marie Skłodowska–Curie actions, Horizon 2020, ERA, EIT KIC</keywords></article-meta></front><body/><back><ref-list><ref id="B1" content-type="article"><label>1</label><element-citation publication-type="journal"><p>1. The Innovative Medicines Initiative (IMI) n.d., viewed Feb 12, 2015, &amp;lt;http://www.imi.europa.eu/&amp;gt;2. The Innovative Medicines Initiative (IMI) research agenda creating biomedical R&amp;amp;D leadership for Europe to benefit patients and society n.d., viewed Feb 12, 2015, &amp;lt;http://www.imi.europa.eu/sites/default/files/uploads/documentzs/imi-gb-006v2-15022008-research-agenda_en.pdf&amp;gt;3. European medicines research training network n.d., viewed Feb 24, 2015, &amp;lt;www.emtrain.eu&amp;gt;4. European programme in pharmacovigilance and pharmacoepidemiology n.d., viewed Feb 24, 2015, &amp;lt;www.eu2p.org&amp;gt;5. Pharmaceutical medicine training programme n.d., viewed Feb 24, 2015, &amp;lt;www.pharmatrain.eu&amp;gt;6. European modular education and training programme in safety sciences for medicines n.d., viewed Feb 24, 2015, &amp;lt;www.safescimet.eu&amp;gt;7. European patient academy for therapeutic innovation n.d., viewed Feb 24, 2015, &amp;lt;www.patientsacademy.eu&amp;gt;8. Pharmatrain library of free e-learning programmes n.d., viewed Feb 24, 2015, &amp;lt;http://pharmatrain.eu/e-library/index.php&amp;gt;9. Payton A, Janko C, Renn O, et al. 2013, on-course&amp;reg; portal: a tool for in-service training and career development for biomedical scientists, Drug Discovery Today, vol.18 (17&amp;ndash;18): 803&amp;ndash;806. http://dx.doi.org/10.1016/j.drudis.2013.04.004.10. on-course&amp;reg; database n.d., viewed Feb 24, 2015, &amp;lt;www.on-course.eu&amp;gt;11. Klech H, Brooksbank C, Price S, et al. 2012, European initiative towards quality standards in education and training for discovery, development and use of medicines. European Journal of Pharmaceutical Sciences, vol.45 (5): 515&amp;ndash;520. http://dx.doi.org/10.1016/j.ejps.2011.12.005.12. LifeTrain Framework for CPD in the Biomedical Sciences n.d., viewed Feb 14, 2015, &amp;lt;www.lifetrain.eu&amp;gt;13. Hardman M, Brooksbank C, Johnson C, et al. 2013, LifeTrain: towards a European framework for continuing professional development in biomedical sciences, Nature Reviews Drug Discovery, vol.12: 407&amp;ndash;408. http://dx.doi.org/10.1038/nrd4026.14. Honorio S, Stonier P, Buhler F, et al. 2013, Core competencies for pharmaceutical physicians and drug development scientists. Frontiers in Pharmacology, vol. 4: 105. http://dx.doi.org/10.3389/fphar.2013.00105.15. Safer and faster evidence-based translation n.d., viewed Feb 24, 2015, &amp;lt;www.imi-safe-t.eu&amp;gt;16. ESFRI BMS Research Infrastructures n.d., viewed Feb 24, 2015, &amp;lt;http://ec.europa.eu/research/infrastructures/pdf/esfri-strategy_report_and_roadmap.pdf&amp;gt;17. European Research Area (ERA) n.d., viewed Feb 24, 2015, &amp;lt;http://ec.europa.eu/research/era/era_communication_en.htm&amp;gt;18. European Clinical Research Infrastructure Network (ECRIN-ERIC) n.d., viewed Feb 24, 2015, &amp;lt;http://www.ecrin.org/&amp;gt;19. Bio-banking and Bio-molecular Resources Infrastructure (BBMRI-ERIC) n.d., viewed Feb 24, 2015, &amp;lt;http://bbmri-eric.eu/&amp;gt;20. European Infrastructure for Translational Medicine (EATRIS-ERIC) n.d., viewed Feb 24, 2015, &amp;lt;http://www.eatris.eu/&amp;gt;21. European Life-sciences Infrastructure for Biological Information (ELIXIR/EMBL) n.d., viewed Feb 24, 2015, &amp;lt;http://www.elixir-europe.org/&amp;gt;22. European Research Infrastructure for Phenotyping and Archiving of Model Mammalian Genomes (INFRAFRONTIER GmBH) n.d., viewed Feb 24, 2015, &amp;lt;https://www.infrafrontier.eu/&amp;gt;23. Structural Biology Research Infrastructure (INSTRUCT) n.d., viewed Feb 24, 2015, &amp;lt;https://www.structuralbiology.eu/&amp;gt;24. INFRASUPP-3 n.d., viewed Feb 24, 2015, &amp;lt;http://www.2020-horizon.com/Strengthening-the-human-capital-of-research-infrastructures-i1493.html&amp;gt;25. Boeynaems J-M, Canivet C, Chan A, et al. 2013, A European approach to clinical investigator training, Frontiers in Pharmacology, vol.4: 112. http://dx.doi.org/10.3389/fphar.2013.00112.26. Marie Skłodowska&amp;ndash;Curie Actions (MSCA) n.d., viewed Feb 24, 2015, &amp;lt;http://ec.europa.eu/programmes/horizon2020/en/h2020-section/marie-sklodowska-curie-actions&amp;gt;27. The European &amp;amp; Developing Countries Clinical Trials Partnership (EDCTP) n.d., viewed Feb 24, 2015, &amp;lt;http://www.edctp.org/&amp;gt;28. Horizon 2020 n.d., viewed Feb 24, 2015, &amp;lt;http://ec.europa.eu/programmes/horizon2020/&amp;gt;29. European Institute of Innovation and Technology n.d., viewed Feb 14, 2015, &amp;lt;http://eit.europe.eu/&amp;gt;30. KIC in Healthy Living and Active Ageing n.d., viewed Feb 24, 2015, &amp;lt;http://eit.europa.eu/eit-community/eit-health&amp;gt;31. Erasmus+ n.d., viewed Feb 24, 2015, &amp;lt;http://ec.europa.eu/programmes/erasmus-plus/index_en.htm&amp;gt;</p><pub-id pub-id-type="doi"/></element-citation></ref></ref-list></back></article>
